| pubmed-article:2200173 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2200173 | lifeskim:mentions | umls-concept:C0035820 | lld:lifeskim |
| pubmed-article:2200173 | lifeskim:mentions | umls-concept:C0034693 | lld:lifeskim |
| pubmed-article:2200173 | lifeskim:mentions | umls-concept:C0024320 | lld:lifeskim |
| pubmed-article:2200173 | lifeskim:mentions | umls-concept:C0018787 | lld:lifeskim |
| pubmed-article:2200173 | lifeskim:mentions | umls-concept:C0450127 | lld:lifeskim |
| pubmed-article:2200173 | lifeskim:mentions | umls-concept:C1456820 | lld:lifeskim |
| pubmed-article:2200173 | lifeskim:mentions | umls-concept:C0035015 | lld:lifeskim |
| pubmed-article:2200173 | lifeskim:mentions | umls-concept:C0038952 | lld:lifeskim |
| pubmed-article:2200173 | lifeskim:mentions | umls-concept:C1882923 | lld:lifeskim |
| pubmed-article:2200173 | lifeskim:mentions | umls-concept:C1548437 | lld:lifeskim |
| pubmed-article:2200173 | lifeskim:mentions | umls-concept:C0281176 | lld:lifeskim |
| pubmed-article:2200173 | lifeskim:mentions | umls-concept:C2349975 | lld:lifeskim |
| pubmed-article:2200173 | lifeskim:mentions | umls-concept:C0332120 | lld:lifeskim |
| pubmed-article:2200173 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:2200173 | pubmed:dateCreated | 1990-9-13 | lld:pubmed |
| pubmed-article:2200173 | pubmed:abstractText | In the previous study we demonstrated that circulating levels of TNF-alpha are elevated during liver allograft rejection and may precede clinical manifestations. The current study was designed to investigate the efficacy of antibody therapy against tumor necrosis factor-alpha and lymphotoxin (LT) in a rat heterotropic cardiac transplant model utilizing Buffalo donors and Lewis recipients. Control animals received no immunotherapy and experienced rejection on postoperative day 11 +/- 0.4 (mean +/- SEM). Experimental animals received immunotherapy either intraperitoneal or intravenous from days 1 to 10. The i.p. administered anti-TNF-alpha prolonged graft survival to 16 +/- 2.7 days (P less than 0.05 vs. controls); the i.v. administration prolonged survival to 15 +/- 1.4 days (P less than 0.004). Animals treated with i.p. anti-LT survived 17 +/- 1.7 days (P less than 0.002 vs. controls). Combination immunotherapy of anti-TNF-alpha and anti-LT increased function to 21 +/- 2.2 days (P less than 0.001 vs controls). Conversely, administration of purified TNF-alpha or LT to graft recipients accelerated the time to rejection. Mean survival for both treatments was 7 days (P less than 0.001 vs. controls). Histologic examination of the transplanted cardiac tissue showed a typical pattern for acute rejection; there was no evidence of hemorrhagic or coagulative necrosis. In contrast, administration of purified TNF-alpha or LT to recipients of a syngeneic heart did not stimulate rejection. These data suggest that TNF-alpha and LT may play a role in the pathogenesis of acute allograft rejection. In addition, the mechanism appears to be distinct from that seen in TNF-alpha or LT-mediated cytotoxicity of tumor cells. | lld:pubmed |
| pubmed-article:2200173 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2200173 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2200173 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2200173 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2200173 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2200173 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2200173 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2200173 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:2200173 | pubmed:issn | 0041-1337 | lld:pubmed |
| pubmed-article:2200173 | pubmed:author | pubmed-author:TerasakiP IPI | lld:pubmed |
| pubmed-article:2200173 | pubmed:author | pubmed-author:HaroGG | lld:pubmed |
| pubmed-article:2200173 | pubmed:author | pubmed-author:BusuttilR WRW | lld:pubmed |
| pubmed-article:2200173 | pubmed:author | pubmed-author:OlthoffK MKM | lld:pubmed |
| pubmed-article:2200173 | pubmed:author | pubmed-author:SeuPP | lld:pubmed |
| pubmed-article:2200173 | pubmed:author | pubmed-author:DempseyR ARA | lld:pubmed |
| pubmed-article:2200173 | pubmed:author | pubmed-author:MillisJ MJM | lld:pubmed |
| pubmed-article:2200173 | pubmed:author | pubmed-author:ImagawaD KDK | lld:pubmed |
| pubmed-article:2200173 | pubmed:author | pubmed-author:WasefE MEM | lld:pubmed |
| pubmed-article:2200173 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2200173 | pubmed:volume | 50 | lld:pubmed |
| pubmed-article:2200173 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2200173 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2200173 | pubmed:pagination | 189-93 | lld:pubmed |
| pubmed-article:2200173 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:2200173 | pubmed:meshHeading | pubmed-meshheading:2200173-... | lld:pubmed |
| pubmed-article:2200173 | pubmed:meshHeading | pubmed-meshheading:2200173-... | lld:pubmed |
| pubmed-article:2200173 | pubmed:meshHeading | pubmed-meshheading:2200173-... | lld:pubmed |
| pubmed-article:2200173 | pubmed:meshHeading | pubmed-meshheading:2200173-... | lld:pubmed |
| pubmed-article:2200173 | pubmed:meshHeading | pubmed-meshheading:2200173-... | lld:pubmed |
| pubmed-article:2200173 | pubmed:meshHeading | pubmed-meshheading:2200173-... | lld:pubmed |
| pubmed-article:2200173 | pubmed:meshHeading | pubmed-meshheading:2200173-... | lld:pubmed |
| pubmed-article:2200173 | pubmed:meshHeading | pubmed-meshheading:2200173-... | lld:pubmed |
| pubmed-article:2200173 | pubmed:meshHeading | pubmed-meshheading:2200173-... | lld:pubmed |
| pubmed-article:2200173 | pubmed:year | 1990 | lld:pubmed |
| pubmed-article:2200173 | pubmed:articleTitle | The role of tumor necrosis factor in allograft rejection. II. Evidence that antibody therapy against tumor necrosis factor-alpha and lymphotoxin enhances cardiac allograft survival in rats. | lld:pubmed |
| pubmed-article:2200173 | pubmed:affiliation | Department of Surgery, University of California, Los Angeles School of Medicine 90024. | lld:pubmed |
| pubmed-article:2200173 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2200173 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:2200173 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2200173 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2200173 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2200173 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2200173 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2200173 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2200173 | lld:pubmed |
